Biologic Drugs With Mechanism of Action: CD20-directed Antibody Interactions
Biologic Drugs With Mechanism of Action: CD20-directed Antibody Interactions
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | 1997-11-26 | ⤷ Start Trial | ⤷ Start Trial |
| Novartis Pharmaceuticals Corporation | ARZERRA | ofatumumab | Injection | 125326 | 2009-10-26 | ⤷ Start Trial | ⤷ Start Trial |
| Novartis Pharmaceuticals Corporation | ARZERRA | ofatumumab | Injection | 125326 | 2009-10-26 | 10,065,011 | ⤷ Start Trial |
| Novartis Pharmaceuticals Corporation | ARZERRA | ofatumumab | Injection | 125326 | 2009-10-26 | 10,081,699 | ⤷ Start Trial |
| Novartis Pharmaceuticals Corporation | ARZERRA | ofatumumab | Injection | 125326 | 2009-10-26 | 10,258,661 | ⤷ Start Trial |
| Novartis Pharmaceuticals Corporation | ARZERRA | ofatumumab | Injection | 125326 | 2009-10-26 | 10,507,255 | ⤷ Start Trial |
| Novartis Pharmaceuticals Corporation | ARZERRA | ofatumumab | Injection | 125326 | 2009-10-26 | 10,738,321 | ⤷ Start Trial |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Patent Expiration |
